Berlin, Berlin, Germany
I'm a scientist & biopharma strategist with an unusual combination of research depth and business experience, and a growing focus on where the two meet in drug discovery, strategy, and healthcare innovation My research career spans a PhD in Immunology and postdoctoral work in the laboratory of Nobel Laureate Emmanuelle Charpentier (CRISPR); years at the bench that built both deep technical fluency and a rare ability to evaluate scientific claims critically and independently. That foundation translated naturally into strategy. At Scitaris I delivered scientific due diligence and investment-ready analyses across multiple advisory projects, covering technology and asset evaluation, competitive landscapes, and early-stage company assessments in oncology, rare diseases, gene therapy, and neurology. I then moved to AICURA medical, an AI-driven clinical development company, where I lead business development while working closely with data science and engineering teams, building hands-on knowledge of how AI is reshaping clinical development and drug discovery, integrating LLM-based tools into daily scientific workflows, and developing a critical eye for evaluating AI-generated outputs against biological and clinical ground truth. Outside of AICURA, I'm co-founding a digital health platform in the veterinary space targeting the DACH and Italian markets (at MVP stage, beginning commercial validation). Open to conversations about roles in drug discovery, life sciences investing, scientific advisory, or strategy at the intersection of science and healthcare innovation.
• Lead the BD function, managing the team, participating as a standing member in C-level strategy meetings, and driving the commercial agenda across outreach, partnerships, and investor engagement • Work closely with the data science and engineering teams to bring scientific and clinical context into product and research discussions around AI models • Integrated LLM-based tools into daily workflows and learned to critically evaluate AI-generated outputs against scientific and clinical ground truth • Built hands-on knowledge of the AI-in-clinical-development landscape and its investment implications • Conducted systematic pipeline analyses of mid-size and large pharma organisations to identify commercial opportunities • Prepared scientific, strategic, and due diligence materials for AICURA's flagship partnership • Produced market analyses and financial projections supporting a major strategic pivot and fundraising
• Promoted to Senior Consultant in 2023 • Worked across 10+ strategic advisory projects for pharma and biotech clients across oncology, rare diseases, gene therapy, and neurology, conducting deep target and asset evaluations and integrating scientific, clinical, and commercial analyses to support R&D prioritisation and portfolio strategy • Served as lead consultant for the end-to-end setup of a pioneering gene-editing company, now at clinical stage: directed technology platform evaluation, competitive landscape analysis, KOL engagement, and regulatory interactions, covering the full scope of early-stage company assessment • Identified and evaluated CROs for clients entering clinical trials, assessing experimental capabilities and data quality to inform outsourcing decisions • Produced investor-ready due diligence reports, scientific dossiers, and strategic assessments for executive and external stakeholders
• Delivered scientific and competitive analyses for pharma and biotech clients across multiple therapeutic areas • Built the underlying research, target/asset assessments, and evidence syntheses that fed client recommendations, coordinating input from researchers, clinicians, and KOLs
• Independent research in the laboratory of Nobel Laureate Emmanuelle Charpentier (CRISPR pioneer, Chemistry 2020), applying gene-editing approaches to study host–pathogen interactions and innate immune responses during Streptococcus pyogenes and SARS-CoV-2 infection • Established novel high-throughput screening methodologies; findings contributed to a peer-reviewed publication in EMBO Reports (2025) • Informally mentored doctoral researchers on immunology projects
• Identified a novel role of Toll-like receptor 8 (TLR8) in bacterial RNA recognition and its role in shaping the adaptive immune response with implications for vaccine design. • Published as first author in Nature Immunology (2018); cited 170+ times; Co-author on a second Nature Immunology publication on macrophage metabolism and host defense (2016) • Presentations at international scientific conferences; Best Poster Award
• Contributed to a pan-European consortium studying genome evolution and immune system origins in marine organisms; work co-published in Science (2010) • Funded through the Marie Curie Initial Training Network programme (ITN Evonet) — a competitive European Commission fellowship